Exozymes Inc. (EXOZ) stock
EXOZNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$3.38−0.05 (-1.46%)
Close on Nov 19, 2026Market cap $31.37MP/E –Yield –
Exozymes free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Exozymes's free cash flow for the twelve months ending Sep 30, 2026 was -$7.80M. For fiscal 2025 it was -$6.67M.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$6.67M | – |
| FY2024 | Dec 31, 2024 | -$8.90M | – |
| FY2023 | Dec 31, 2023 | -$1.47M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$2.53M | – |
| Q2 FY2026 | Jun 30, 2026 | -$1.64M | – |
| Q1 FY2026 | Mar 31, 2026 | -$1.58M | – |
| Q4 FY2025 | Dec 31, 2025 | -$2.05M | – |
| Q3 FY2025 | Sep 30, 2025 | -$1.87M | – |
| Q2 FY2025 | Jun 30, 2025 | -$1.59M | – |
| Q1 FY2025 | Mar 31, 2025 | -$1.16M | -979.7% |
| Q4 FY2024 | Dec 31, 2024 | -$5.92M | – |
| Q3 FY2024 | Sep 30, 2024 | -$541.52K | – |
| Q2 FY2024 | Jun 30, 2024 | -$2.58M | – |
| Q1 FY2024 | Mar 31, 2024 | $132.39K | – |
| Q4 FY2023 | Dec 31, 2023 | -$893.02K | – |
See a number that looks wrong?